← Eichor
Condition: Tumor Infiltrating Lymphocytes Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tumor Infiltrating Lymphocytes

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of TIL in Advanced Solid Tumors (DFGD)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT06488950KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Phase 1 · 2 location(s) · Christian Hinrichs · NCT05483491Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07443020The Lymphocytic Infiltrate of Lung Tumors.
Phase N/A · 1 location(s) · Scientific Institute San Raffaele · NCT06470607Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
NA · 1 location(s) · Grit Biotechnology · NCT06190275A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Phase 2 · 12 location(s) · Iovance Biotherapeutics, Inc. · NCT06481592TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06640582To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
NA · 1 location(s) · Yong Wha Moon · NCT07651124TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT06455917A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT05142475Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Phase 2 · 1 location(s) · Dan Zandberg · NCT04114136Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell
Phase N/A · 1 location(s) · University of Jena · NCT04902937A Phase II Trial of LM103 in Advanced Melanoma
Phase 2 · 13 location(s) · Suzhou BlueHorse Therapeutics Co., Ltd. · NCT07310784Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06047977Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
EARLY_Phase 1 · 3 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT05831033T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT06783270TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
Phase 2 · 5 location(s) · D'Or Institute for Research and Education · NCT07074106A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
EARLY_Phase 1 · 1 location(s) · Shanghai Juncell Therapeutics · NCT04960072To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Phase 1 · 2 location(s) · Inge Marie Svane · NCT06204991Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Phase 1 · 1 location(s) · David Bartlett, MD · NCT07192900Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1/Phase 2 · 10 location(s) · Obsidian Therapeutics, Inc. · NCT06060613Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06598371Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT01174121Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours
NA · 3 location(s) · Grit Biotechnology · NCT06397963Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tu
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06630611E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/Phase 2 · 2 location(s) · Christian Hinrichs · NCT05639972GT201 Injection For The Treatment Of Advanced Solid Tumors
Phase 1/Phase 2 · 4 location(s) · Grit Biotechnology · NCT06144671Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Dan Zandberg · NCT06052839
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.